) Surrogate endpoints can be useful in phase I/II screening trials for identifying whether a new intervention is biologically active and for guiding decisions about whether the intervention is promising enough to justify a large definitive trial with clinically meaningful outcomes. Based on pre-clinical studies of biologic activity generated in the applicant's laboratory, sodium phenylbutyrate, an aromatic fatty acid, represents a potentially non-toxic, non-retinoid differentiating agent for use in the care of patients with prostate cancer and glioblastoma. To date, the role of differentiation therapy in the advanced, clinically progressing prostate cancer patient has not been defined or appropriately explored. Differentiation therapy lacks the allure of cytoreductive strategies and is likely to provide disease stabilization as a therapeutic endpoint. Given the projected, yet untested, endpoint of differentiation therapy using non-toxic agents, assessment of bioactivity is critical to the advancement and early clinical evaluation of agents such as phenylbutyrate. Two clinical trials evaluating continuous phenylbutyrate exposure, either through thrice daily oral administration (phase I), or by continuous intravenous infusion (phase II), provide the framework to develop, evaluate, and begin the process of validation of surrogate endpoints specific for prostate cancer in response to differentiation therapy. Specifically, the clinical trials will generate safety and toxicity data and efficacy data of phenylbutyrate in patients with prostate cancer. Using patient-derived samples, the laboratory aims to determine the patterns and the importance of cytokine alterations (IL-6, VEGF, ET-1), changes in prostate specific membrane antigen expression (PSMA, PSA), and the induction of cell cycle proteins associated with differentiation or growth arrest (p2lwaf1/cip, cyclin D1) in patients after phenylbutyrate treatment. Harvesting of large numbers of circulating, viable prostate cancer cells will provide the research material needed to assess in vivo inhibition of telomerase activity and effects of phenylbutyrate on cellular metabolism using NMR. These assays and quantitative bone scan imaging will be correlated with plasma phenylbutyrate levels, clinical response, and outcome in treated prostate cancer patients. This research application will provide new and clinically relevant information on differentiation therapy with phenylbutyrate and assessment of its bioactivity in patients with prostate cancer, as well as potentially identify useful surrogate endpoints of response and bioactivity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA075525-03
Application #
2896175
Study Section
Special Emphasis Panel (ZCA1-CRB-X (M1))
Program Officer
Xie, Heng
Project Start
1997-08-01
Project End
2001-05-31
Budget Start
1999-06-01
Budget End
2000-05-31
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Lin, Jianqing; Gilbert, Jill; Rudek, Michelle A et al. (2009) A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res 15:6241-9
Verheul, Henk M W; Qian, David Z; Carducci, Michael A et al. (2007) Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. Cancer Chemother Pharmacol 60:329-39
Fontes, Aparecida Maria; Davis, Brian M; Encell, Lance P et al. (2006) Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells. Mol Cancer Ther 5:121-8
Rudek, Michelle A; Zhao, Ming; He, Ping et al. (2005) Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 23:3906-11
Gilbert, Jill; Gore, Steve D; Herman, James G et al. (2004) The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin Cancer Res 10:4589-96
Davis, Brian M; Reese, Jane S; Lingas, Karen et al. (2003) Drug selection of mutant methylguanine methyltransferase from different oncoretroviral backbones results in multilineage hematopoietic transgene expression in primary and secondary recipients. J Hematother Stem Cell Res 12:375-87
Gerson, Stanton L (2002) Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20:2388-99
Liu, Lili; Schwartz, Stuart; Davis, Brian M et al. (2002) Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer. Cancer Res 62:3070-6
Wadhwa, Punit D; Zielske, Steven P; Roth, Justin C et al. (2002) Cancer gene therapy: scientific basis. Annu Rev Med 53:437-52
Carducci, M A; Gilbert, J; Bowling, M K et al. (2001) A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 7:3047-55

Showing the most recent 10 out of 25 publications